Please login to the form below

Not currently logged in
Email:
Password:

Lucid adds to senior leadership team

Shula Sarner and Tanya Goodyear join the med comms agency

Lucid Shula SarnerLucid Group has expanded its senior leadership team with the appointments of Shula Sarner and Tanya Goodyear.

Sarner (pictured right) becomes executive scientific director at the medical communications agency, bringing 15 years of experience as a medical researcher in both academic and biotech sectors.

Most recently, Sarner served as global scientific strategy director at integrated medhealth communications (imc), leading scientific strategy and business development across teams.

Prior to this, she held a number of increasingly senior scientific strategy roles at US medical communications agency Lockwood, and served as a scientific director for Medicus International.

Lucid Tanya GoodyearMeanwhile, Goodyear (pictured left) joins Lucid as its immunology division director, bringing 16 years of experience in healthcare communications and medical education.

Goodyear moves from inVentiv Medical Communications, which she joined as senior vice president for medical communications in February 2015 before becoming director of commercial strategy at the beginning of this year.

Her previous experience includes serving as head of project management for OnMedica, an online medical resources and education platform for healthcare professionals, and a medical writer for Adelphi Medi Cine, part of Adelphi.

Goodyear said: “Lucid immediately felt like the perfect team for me - the passion, innovation and creativity running through everything Lucid does translates into world-leading medical education programmes that really do change behaviour.”

5th October 2016

From: PME

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics